Reading the tape
NASDAQ: HOLX
Hologic, Inc.
Healthcare · Medical - Instruments & Supplies
Market Cap
$16.97B
52w High
$76.07
52w Low
$51.90
P/E
31.36
Volume
101.96M
Outstanding Shares
223.24M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 24.06%Revenue (TTM): 2.16%FCF (TTM): -10.37%P/FCF: 57th pct
What changed
The stock rose 24.06% over the last year. Revenue grew 2.16% over the trailing twelve months. Operating margin moved from 23.45% to 17.49%. Free cash flow declined 10.37% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 17.49%. A decisive move in revenue — currently up 2.16% — would be the clearest signal to resolve the ambiguity.
Company profile
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally.
CEOPaul Malenchini
SectorHealthcare
IndustryMedical - Instruments & Supplies
Employees7,063
IPO dateMar 1, 1990
Valuation
Forward P/E—
EV/EBITDA15.57
Enterprise value$15.94B
Stock splits
Apr 3, 2008↑ Forward
Every 1 shares became 2
Dec 1, 2005↑ Forward
Every 1 shares became 2
Mar 26, 1996↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth2.54%
Gross margin52.82%▲10.35%vs FY2024
Operating margin17.49%▼20.45%vs FY2024
ROE11.21%▼27.18%vs FY2024
Analyst consensus
RatingHold
Target price$79.00▲3.93%
18
Buy
23
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est $1.09 · Revenue est $1.03B
View